Presenter Status
Fellow
Abstract Type
Research
Primary Mentor
John Perry, PhD
Start Date
6-5-2022 11:30 AM
End Date
6-5-2022 1:30 PM
Presentation Type
Poster Presentation
Description
Background: Incorporating the immune system into cancer management is an area of robust research. Treatment modalities aimed at activating cytotoxic T cells against malignancies include immune checkpoint inhibitors, bispecific T-cell engagers, and chimeric antigen receptor (CAR) tumor-specific T cells. Most anti-cancer T cell research is narrowly focused, but knowledge about the nature of diverse sub-populations of T cells in cancer, particularly memory T cells, is vital prior to potential incorporation into therapies. T memory stem cells (Tscm) are of interest due to their longevity and powerful abilities of self-renewal and creating the full spectrum of memory CD8+ T cells, including central memory (Tcm) and effector memory cells (Tem).
Objectives/Goal: To determine potential presence and frequency of memory T cell populations in human leukemia at diagnosis and after induction chemotherapy.
Methods/Design: Children’s Mercy Cancer Center Biorepository provided samples from 16 patients with premature B cell acute lymphoblastic leukemia (pre-B ALL) from peripheral blood (PB) and/or bone marrow (BM). Timepoints were diagnosis and day 29 (D29) of induction chemotherapy. Flow cytometric analysis of cytotoxic memory T cell populations was performed and analyzed using descriptive statistics and the t-test.
Results: Despite sample variability, the absolute cell counts were not significantly different. The live cell percent was lower at diagnosis than D29 (PB- 57.2% vs 79.4%, p=0.001; BM- 41.7% vs 77.0%, p
Conclusions: Induction chemotherapy led to decreased differentiated CD8+ T cells with recovery of mostly naïve cells by D29. Furthermore, we established the presence of Tscm in most pediatric pre-B ALL samples. The decline of Tscm in most patients requires functional analyses to determine their role in leukemia and potential for use in immunotherapy.
MeSH Keywords
Leukemia
Included in
Higher Education and Teaching Commons, Medical Education Commons, Neoplasms Commons, Pediatrics Commons, Science and Mathematics Education Commons
Memory T cell Populations in Human Leukemia
Background: Incorporating the immune system into cancer management is an area of robust research. Treatment modalities aimed at activating cytotoxic T cells against malignancies include immune checkpoint inhibitors, bispecific T-cell engagers, and chimeric antigen receptor (CAR) tumor-specific T cells. Most anti-cancer T cell research is narrowly focused, but knowledge about the nature of diverse sub-populations of T cells in cancer, particularly memory T cells, is vital prior to potential incorporation into therapies. T memory stem cells (Tscm) are of interest due to their longevity and powerful abilities of self-renewal and creating the full spectrum of memory CD8+ T cells, including central memory (Tcm) and effector memory cells (Tem).
Objectives/Goal: To determine potential presence and frequency of memory T cell populations in human leukemia at diagnosis and after induction chemotherapy.
Methods/Design: Children’s Mercy Cancer Center Biorepository provided samples from 16 patients with premature B cell acute lymphoblastic leukemia (pre-B ALL) from peripheral blood (PB) and/or bone marrow (BM). Timepoints were diagnosis and day 29 (D29) of induction chemotherapy. Flow cytometric analysis of cytotoxic memory T cell populations was performed and analyzed using descriptive statistics and the t-test.
Results: Despite sample variability, the absolute cell counts were not significantly different. The live cell percent was lower at diagnosis than D29 (PB- 57.2% vs 79.4%, p=0.001; BM- 41.7% vs 77.0%, p
Conclusions: Induction chemotherapy led to decreased differentiated CD8+ T cells with recovery of mostly naïve cells by D29. Furthermore, we established the presence of Tscm in most pediatric pre-B ALL samples. The decline of Tscm in most patients requires functional analyses to determine their role in leukemia and potential for use in immunotherapy.
